BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright cut their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, November 25th.

BioLineRx Stock Performance

BLRX stock opened at $0.27 on Monday. The business’s fifty day moving average is $0.44 and its 200-day moving average is $0.59. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The company has a market cap of $21.59 million, a P/E ratio of -1.28 and a beta of 1.39. BioLineRx has a twelve month low of $0.25 and a twelve month high of $1.89.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Atria Investments Inc increased its position in shares of BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 29,193 shares in the last quarter. PVG Asset Management Corp bought a new stake in shares of BioLineRx in the 2nd quarter valued at $70,000. Finally, CVI Holdings LLC bought a new stake in shares of BioLineRx in the 2nd quarter valued at $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.